Premium Reports
Contact KLAS
 Download Report Brief  Download Full Report    Zoom in charts



Related Series

 No Related Series

 End chart zoom
Allscripts Allscripts
* A page refresh may be necessary to see the updated image

The Merger, the Upgrade and What it Means Today

November 11, 2009

In the midst of the current electronic health record (EHR) frenzy, the recently merged Allscripts-Misys Healthcare Solutions controls the largest ambulatory EMR/EHR client base. Allscripts is also the most-often-considered vendor in the market today, with a historical reputation of flexible software and solid support. At the time the merger with Misys was announced, Allscripts was also engaged in a major overhaul of its Enterprise EHR (TouchWorks). Today, as the dust from that merger continues to settle and many customers contemplate an upgrade to v.11, it can be difficult to get a clear picture of the Allscripts world from a user perspective; and with HITECH deadlines looming, that clear picture is more crucial now than ever before.

In an effort to alleviate provider confusion, KLAS set out to answer a few fundamental questions in this fast moving market: How has the 2008 merger affected Allscripts and Misys customers? What are the go-forward products and strategies now that these vendors have merged? Is it worth the effort for Enterprise users to upgrade to v.11? What pieces of v.11 are working, and which issues remain unresolved? KLAS gathered feedback from 201 Allscripts customers to answer these and other questions.

author - Robert Ellis
Project Manager
Robert Ellis
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.